<DOC>
	<DOC>NCT02552862</DOC>
	<brief_summary>Study Design: Double-blind placebo-controlled clinical trial Study Duration:2 years Study Center: Hospital de la Santa Creu i Sant Pau, Barcelona (single center) Objectives: To assess the effect of adjunctive Vivomixx速 on bacterial translocation in patients with cirrhosis and SBP Number of Subjects: 30 Main Inclusion Criteria: Patients with cirrhosis hospitalized with an episode of SBP at Hospital de la Santa Creu i Sant Pau Study Product, Dose, Route, Regimen: Vivomixx 速 sachets containing 450 x 109 bacteria, 2 every 12 hours during hospitalization (n=15), or placebo (n=15) Duration of administration: During hospitalization due to SBP episode Hypothesis: The adjunctive treatment with Vivomixx速 in patients with cirrhosis and SBP could decrease bacterial translocation and systemic and cerebral proinflammatory state. This would result in a faster SBP resolution, a decrease in the incidence of complications and an improvement in cognitive function.</brief_summary>
	<brief_title>Study of the Effect of Adjunctive Vivomixx速 in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis (SBP)</brief_title>
	<detailed_description />
	<mesh_term>Peritonitis</mesh_term>
	<mesh_term>Silicon</mesh_term>
	<criteria>Patients with cirrhosis hospitalized with an episode of SBP at Hospital de la Santa Creu i Sant Pau. Cirrhosis will be diagnosed by clinical, analytical and ultrasonographic findings or by liver biopsy. SBP will be diagnosed by an ascitic fluid neutrophil count &gt; 250/mm3 with or without positive culture . Advanced hepatocellular carcinoma (beyond Milan's criteria) or any other malignancy. Advanced liver insufficiency [MELD (model for endstage liver disease) &gt;25]. Active alcohol intake (in the previous 3 months). Neurological disease. Marked symptomatic comorbidities (cardiac, pulmonary, renal, untreated active depression, HIV infection). Previous antibiotic treatment, including norfloxacin and rifaximin. Septic shock, ileus, need for tracheal intubation or intensive care unit. Immunomodulatory drugs.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>